Stock Price
64.48
Daily Change
1.44 2.28%
Monthly
4.62%
Yearly
-32.33%
Q2 Forecast
61.81

EPS Reference Time Actual Consensus Previous
2026-04-30 FY2026Q1 PM 0.86 0.89 0.86
2026-02-24 FY2025Q4 PM 1.04 0.95 0.93
2025-10-30 FY2025Q3 PM 0.92 0.83 0.86
2025-07-30 FY2025Q2 PM 1.01 0.95 0.92
2025-04-24 FY2025Q1 PM 0.86 0.83 0.77



Peers Price Chg Day Year Date
Terumo 2,280.00 4.00 0.18% -12.49% Jun/05
Olympus 1,843.50 -38.50 -2.05% -5.46% Jun/05
Abbott 91.07 0.29 0.32% -31.82% Jun/05
AngioDynamics 11.94 -0.09 -0.75% 7.96% Jun/05
Anika Therapeutics 14.48 -0.31 -2.10% 27.58% Jun/05
AtriCure 27.10 -0.17 -0.62% -22.44% Jun/05
Baxter International 19.38 0.03 0.16% -35.96% Jun/05
Becton, Dickinson and Co. 151.16 1.60 1.07% -12.85% Jun/05
Boston Scientific 48.55 -0.30 -0.61% -52.44% Jun/05
Cooper Companies 67.34 5.32 8.58% -6.90% Jun/05

Indexes Price Day Year Date
USND 25709 -1,121.53 -4.18% 31.64% Jun/05
US2000 2834 -101.83 -3.47% 32.89% Jun/05

Merit Medical Systems traded at $64.48 this Friday June 5th, increasing $1.44 or 2.28 percent since the previous trading session. Looking back, over the last four weeks, Merit Medical Systems gained 4.62 percent. Over the last 12 months, its price fell by 32.33 percent. Looking ahead, we forecast Merit Medical Systems to be priced at 61.81 by the end of this quarter and at 58.19 in one year, according to Trading Economics global macro models projections and analysts expectations.

Merit Medical Systems, Inc. designs, develops, manufactures and markets medical products for interventional and diagnostic procedures. The Company’s segments include cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, interventional oncology and spine devices. The endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products, including peripheral intervention, cardiac intervention, custom procedural solutions, original equipment manufacturer and endoscopy.